The effects of three months long continuous glucose monitoring in children with type 1 diabetes on multiple daily insulin injections

Gordana Bukara-Radujković; Vesna Miljković; Siniša Lakić

doi:10.2298/VSP170908106B

Gordana Bukara-Radujković University Clinical Center of the Republic of Srpska, Clinic of Pediatrics, Banja Luka, Bosnia and Herzegovina
Vesna Miljković University Clinical Center of the Republic of Srpska, Clinic of Pediatrics, Banja Luka, Bosnia and Herzegovina
Siniša Lakić University of Banja Luka, Department of Psychology, Banja Luka, Bosnia and Herzegovina

DOI: https://doi.org/10.2298/VSP170908106B

Keywords: diabetes mellitus, type 1;, child; bosnia and herzegovina;, drug monitoring;, insulin;, blood glucose self monitoring.

Abstract

Background/Aim. The Professional System of Continuous Glucose Monitoring, the iPro^®2 CGM System (Medtronic) is designed to be worn together with a glucose sensor with an electrode inserted into the subcutaneous tissue, up to 7 days, without insight into the current level of glycemia. After reading data from the iPro^®2 device, a realistic picture of the glycemia movement during the period of wearing the device is obtained. The aim of the study was to examine whether objective measurement information collected through the use of professional continuous glucose monitoring (CGM) contribute to improved metabolic control in children with type 1 diabetes mellitus who are on the multiple daily insulin injections (MDI). Methods. The study was conducted on 24 patients (14 girls) aged 5 to 18 years, with an average age 12 ± 3.3 years, in the period from June to December 2016 in the Clinic of Pediatrics, University Clinical Center of the Republic of Srpska in Banja Luka. Glycated hemoglobin (HbA1c) was measured in the laboratory at the start of the trial and 3 months afterwards in order to determine the effect of wearing professional iPro^®2 on metabolic control, and then three months later, to test for the long-lasting effects in the absence of iPro^®2 monitoring. Results. The initial HbA1c was 7.78 ± 1.17% (min: 5.50%; max: 10.00%). After 3 months, HbA1c showed a statistically significant decrease to 7.34 ± 0.84% (min: 5.60%, max: 8.90%). At the six-month follow-up visit, without implementing professional CGM in the meantime, a significant increase in HbA1c was reached, with the average value of 7.68% ± 0.83% (min: 5.50%, max: 9.10%). Conclusion. This study shows that carrying a professional CGM for 7 days per month, 3 months continuously is associated with certain improvement of metabolic control in children with diabetes who are on MDI without increasing risks of hypoglicemia.

References

Garg SK. The Future of Glucose Monitoring. Diabetes Tech-nol Ther 2016; 18 Suppl 2: S2iv-22.

Pickup JC, Freeman SC, Sutton AJ. Glycemic control in type 1 diabetes during real time continuous glucose monitoring com-paring with self-monitoring of blood glucose: a meta-analysis of randomized controlled trials using individual patient data. BMJ 2011; 343: d3805.

Battelino T, Conget B, Olsen B, Schütz-Fuhrmann I, Hommel E, Hoogma R. The use and efficacy of continuous glucose moni-toring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 2012; 55(12): 3155–62.

Battelino T, Philip M, Bratina N, Nimri R, Oskarsson P, Bolinder J. Effect of continuous glucose monitoring on hypoglycaemia in type 1 diabetes. Diabetes Care 2011; 34(4): 795–800.

Garg SK. Role of Continuous Glucose Monitoring in Patients with diabetes using multiple daily insulin injections. Infusys-tems USA 2009; 6: 9–14.

Foster NC, Miller KM, Tamborlane WV, Bergenstal RM, Beck RW. Continuous glucose monitoring in patients with type 1 diabetes using insulin injections. Diabetes Care 2016; 39(6): e81–2.

Bachmann S, Hess M, Martin-Diener ,Denhaerynck K, Zumsteg U. Nocturnal hypoglycemia and physical activity in children with diabetes: new insights by continuous glucose monitoring and accelerometry. Diabetes Care 2016; 39(7): e95–6.

Bode WB, Battelino T. Continuous Glucose Monitoring in 2016. Diabetes Technol Ther 2017; 19(S1): S11–S18.

Zschornack E, Schmid C, Pleus S, Link M, Klötzer HM, Obermaier K, et al. Evaluation of the Performance of a Novel System for Continuous Glucose Monitoring. J Diabetes Sci Technol 2013; 7(4): 815–23.

Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Beck RW, Buckingham B, Miller K, Wolpert H, Xing D, Block JM, et al. Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes. Diabe-tes Care 2009; 32(11): 1947–53.

Beck RW, Riddlesworth T, Ruedy K, Ahmann A, Bergenstal R, Haller S, et al. DIAMOND Study Group. Effect of Continu-ous Glucose Monitoring on Glycemic Control in adults with type 1 diabetes using insulin injections: The DIAMOND Ran-domized Clinical Trial. JAMA 2017; 317(4): 371–8.

Battelino T, Liabat S, Veeze HJ, Castaneda J, Arrieta A, Cohen O. Routine use of continuous glucose monitoring in 10501 peo-ple with diabetes mellitus. Diabet Med 2015; 32(12): 1568–74.

Bailey TS, Chang A, Christiansen M. Clinical accuracy of a con-tinuous glucose monitoring system with an advanced algo-rithm. J Diabetes Sci Technol 2015; 9(2): 209–14.

Christansen M, Bailey T, Watkins E, Liljenquist D, Price D, Na-kamura K, et al. A new-generation continuous glucose moni-toring system: improved accuracy and realability compared with a previous – generation system. Diabetes Technol Ther 2013; 15(10): 881–8.

American Diabetes Association. 11. Children and Adolescents. Diabetes Care 2016; 39 Suppl 1: S86–93.

Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Validation of measures of satisfaction with and impact of continuous and conventional glucose monitoring. Diabetes Technol Ther 2010; 12(9): 679-84.

Rewers MJ, Pillary K, de Beaufort C, Craig ME, Hanas R, Acerini CL, et al. Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes 2014; 15(Suppl 20): 102–14.

Bell KJ, Smart CE, Steil GM, Brand-Miller JC, King B, Wolpert HA. Impact of fat, protein, and glycemic index on postpran-dial glucose control in type 1 diabetes: implications for inten-sive diabetes management in the continuous glucose monitor-ing era. Diabetes Care 2015; 38(6): 1008–15.

Hirsch IB. Glycemic variability and diabetes complications: does it matter? Of course it does! Diabetes Care 2015; 38(8): 1610–4.

Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Grou. Beck RW, Hirsh IB, Laffel L, Tamborlane WV, Bode BW, Buckingham B,et al. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care 2009; 32(8): 1378–83.

El Youssef J, Ward WK. Treatment Challenges for the Young Patient with Type 1 Diabetes. Diabetes Technol Ther 2015; 17(6): 367–9.

Telo GH, Volkening LK, Butler DA, Laffel LM. Salient Charac-teristics of Youth With Type 1 Diabetes Initiating Continuous Glucose Monitoring. Diabetes Technol Ther 2015; 17(6): 373–8.